344 related articles for article (PubMed ID: 26733616)
1. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
[TBL] [Abstract][Full Text] [Related]
2. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
4. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
[TBL] [Abstract][Full Text] [Related]
6. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
8. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
9. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
10. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
[TBL] [Abstract][Full Text] [Related]
11. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
Tsim S; Alexander L; Kelly C; Shaw A; Hinsley S; Clark S; Evison M; Holme J; Cameron EJ; Sharma D; Wright A; Grundy S; Grieve D; Ionescu A; Breen DP; Paramasivam E; Psallidas I; Mukherjee D; Chetty M; Cox G; Hart-Thomas A; Naseer R; Edwards J; Daneshvar C; Panchal R; Munavvar M; Ostroff R; Alexander L; Hall H; Neilson M; Miller C; McCormick C; Thomson F; Chalmers AJ; Maskell NA; Blyth KG
J Thorac Oncol; 2021 Oct; 16(10):1705-1717. PubMed ID: 34116230
[TBL] [Abstract][Full Text] [Related]
12. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
[TBL] [Abstract][Full Text] [Related]
13. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
15. ATG5 as biomarker for early detection of malignant mesothelioma.
Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
[TBL] [Abstract][Full Text] [Related]
16. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
17. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
20. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
